The Asia Pacific Bronchodilators Market would witness market growth of 4.6% CAGR during the forecast period (2022-2028).
The bronchodilators come in two forms which are short-acting and long-acting bronchodilators. Short-acting bronchodilators stop or provide relief from sudden symptoms of asthma quickly. They are effective for three to six hours. They are also known as a rescue inhaler. Inhalers are canisters of medicine in a plastic holder with a mouthpiece.
The steps theory in managing reversible lung diseases like asthma incorporates long- and short-acting bronchodilators. Those with intermittent asthma should get a short-acting bronchodilator like albuterol as per requirement. For more symptomatic disease, adding a low-dose inhaled corticosteroid is generally the next step, followed by adding a long-acting bronchodilator with the inhaled steroid. The increment in the aggressive treatment should differ from those who specialize in allergy and asthma treatment.
After achieving control, the patient can consult with their doctor to change these medications to a smaller dose with fewer adverse effects. Failure to control symptoms with short or long-acting corticosteroids and bronchodilators can cause irreversible lung injury. Frequent monitoring through pulmonary function tests and peak airway flow is essential for the success of the treatment.
China is the biggest consumer and producer of tobacco globally. There are more than 300 million smokers in China, which is around one-third of the world’s total. In China, more than half of adult men are tobacco smokers. About one in every three cigarettes smoked is in China. In addition, over 700 million non-smokers in China, including 180 million children, are exposed to second-hand smoke at least once a day a week. The high level of tobacco consumption will increase the number of respiratory cases and the utilization of bronchodilators medication, thus propelling the market growth in the region.
The China market dominated the Asia Pacific Bronchodilators Market by Country in 2021; thereby, achieving a market value of $1,709.1 million by 2028. The Japan market is registering a CAGR of 4% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 5.2% during (2022 - 2028).
Based on Drug Class, the market is segmented into Beta-Adrenergic, Xanthine Derivatives, and Anticholinergic. Based on Route of Administration, the market is segmented into Nasal (Inhalable), Oral, and Injectable. Based on Disease, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Bronchodilators Market is Projected to reach USD 27 Billion by 2028, at a CAGR of 3.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.
By Drug Class
By Route of Administration
By Disease
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
